An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Talzenna

Chemical Nametalazoparib
Dosage FormCapsule (oral; 0.25 mg, 0.5 mg, 1 mg)
Drug ClassInhibitors
SystemFemale reproductive
CompanyPfizer Inc.
Approval Year2018

Indication

  • To treat deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.
Last updated on 12/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Talzenna (Talazoparib) Prescribing Information 2018Pfizer Inc., New York, NY
Document TitleYearSource
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.2018The New England Journal of Medicine
Document TitleYearSource
Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. 2020Journal of Clinical Oncology